co nyse qq
coronaviru affect drug firm moat
page full analyst note apr
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim
price data apr
rate updat apr
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
innov cultur strong financi commit
develop next gener drug set compani apart
peer fuel long-term growth follow steep
patent cliff lilli growth prospect improv
compani launch sever new blockbust patent loss
fade
lilli intern pipelin well posit mitig patent
loss next decad compani tend spend
sale financ develop effort new drug
much higher midteen industri averag robust
pipelin result lilli strong commit research
believ recent approv diabet drug trulic tradjenta
jardianc immunolog drug taltz olumi hold
highest sale potenti lilli new drug also sever lilli
cancer drug cyramza verzenio develop
blockbust addit clinic data hold
lilli strong entrench insulin product also help
compani deal patent loss unlik tradit drug
lilli insulin drug hard copi gener creat
barrier entri noninsulin produc larg
up-front invest need creat scale effici
lilli longer-act biosimilar insulin help compani
secur market share
compani take hard look bottom line
combin cost save expect top-lin growth lilli
aim reach oper margin believ
achiev lilli expect increas gross margin
product initi greater capac util overal
view strong traction recent launch high-margin drug
immunolog oncolog support overal profit gain
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note adjust ep use adjust share count million
eli lilli pharmaceut compani focu neurosci
endocrinolog oncolog immunolog lilli key product includ
alimta verzenio cancer forteo osteoporosi jardianc trulic
humalog humulin diabet taltz olumi immunolog
ciali erectil dysfunct
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qq
coronaviru affect drug firm moat
slightli lower pharma
fair valu estim almost aggreg much less
stock declin result disrupt
caus coronaviru outbreak high need drug
support continu demand suppli also
expect new treatment vaccin reduc long-
term impact viru expect chang
moat rate innov continu minor
disrupt success coronaviru treatment
pharmaceut industri also remind world
social import group key esg factor
industri shield potenti pressur
look bigger pictur around coronaviru
challeng view four key point drug biotech
industri first expect much impact drug sale
econom disrupt coronaviru caus
drug demand tend highli inelast
govern like priorit drug suppli second
drug util near term like face disrupt
especi new drug drug new indic
expect entrench drug face minor
impact third beyond capit appreci view
dividend group secur averag pay-out
ratio close give firm room adapt near-
term coronaviru pressur last expect new medicin
vaccin emerg treat coronaviru limit
background outlook coronaviru
impact pharma industri
pleas see report titl coronaviru caus limit
impact pharma moat valuat
dividend look attract market pullback
lower fair valu estim
base coronaviru disrupt primarili relat
compani new drug expect major
swing lilli diabet franchis expect slower
uptak new patient trulic jardianc cut
close growth also expect slow
trajectori growth migrain drug emgal cancer
drug verzenio immunolog drug taltz collect
take addit growth despit
drug like grow slower rate lilli fairli
defens portfolio drug critic need
patient see much disrupt
aggreg compani look well posit drive
top-lin growth project annual sale increas
next five year result new drug launch
offset patent loss particular outlook
immunolog drug taltz olumi appear strong
clinic data support drug becom leader
immunolog expect diabet drug jardianc
trulic along cancer drug cyramza becom
increasingli import driver cash flow particular
jardianc look pois hit peak sale project
billion base strong cardiovascular data anoth
import point drive valuat cost control
increasingli think lilli abl meet estim
achiev oper margin close
improv
outcom oper cost control depend new
revenu associ success recent launch
drug pipelin expect lilli reach goal
longer term expect strength lilli product
portfolio drive addit margin gain
oper margin line compani
guidanc estim weight cost capit lilli
line peer group
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qq
patent economi scale power distribut
drug carri strong price power enabl firm
gener return invest capit excess cost
capit patent give compani time
develop next gener drug gener
mean compani top drug repres moder
amount total sale largest drug trulic
repres total sale set manag
cash flow declin new product mitig gener
competit also lilli oper structur allow
cost-cut patent loss reduc margin
pressur lost high-margin drug sale overal lilli
establish product line creat enorm cash flow
need fund averag million develop
cost per new drug addit compani power
distribut network set compani strong partner
smaller drug compani lack lilli resourc lilli
entrench insulin franchis creat ad layer
competit advantag
competit seem mani year away due complex
gain gener approv insulin high cost
build need economi scale insulin product
hurdl tradit small molecul biosimilar
gain market share follow eventu patent expir
given deceler patent loss strong pipelin
believ moat trend stabl next five
year compani key patent loss includ erectil
dysfunct drug ciali osteoporosi drug forteo
potenti cancer drug alimta patent loss
next five year affect close total sale
compani strong pipelin combin stabl current
market drug lead annual revenu
probabl bear case
larg base low volatil cash flow
divers inelast product portfolio rate lilli
uncertainti medium larg line
pharma peer group howev lilli slightli
uncertainti partli high product concentr
risk surround pipelin recent launch drug
repres one fifth sale end
next year scenario analysi assum
base-cas fair valu estim bull case
probabl project fair valu estim rel
base case scenario analysi show moder
varianc henc medium uncertainti rate factor
affect scenario analysi includ degre
success brand drug pipelin magnitud
market pressur current market drug larg
amount valuat driven pipelin success
new drug launch clinic trial amplifi
impact lilli valuat ad potenti
 healthcar polici reform relat drug price
bear case creat addit pressur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qq
growth period pipelin side
expect billion peak annual sale psoriasi
drug taltz rheumatoid arthriti drug olumi also
strong cardiovascular data lilli diabet drug trulic
drive drug peak annual sale
macro environ lilli sever headwind
make solid strateg move address challeng
neg side risk-sensit food drug
administr gener approv safe drug
drug high-ne area cancer also
managed-car organ pharmaci benefit
manag consolid past decad
use grow size demand lower drug price
reduc coverag less innov drug forc drug
firm push true innov reduc power
lilli distribut network govern
evalu compar effect program
aggress price negoti rais bar futur
innov lilli sever headwind pipelin
hold sever biolog drug hold much stronger
competit advantag tradit small molecul
compani pipelin focus
innov treatment area unmet medic need
payer coverag price power remain strong
outsid pipelin compani strong insulin franchis
sale carri extra protect award
biolog economi scale need produc
rel lower-pr drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qq
olilli launch new immunolog drug taltz
olumi offer better efficaci stronger
safeti profil tnf drug like set multi-
oth divestitur anim healthcar group
enabl lilli focu higher-margin human
olilli lag immuno-oncolog market may
creat competit headwind older cancer
osever lilli recent launch diabet drug
year behind competit launch
lack differenti could slow market share
olilli increas focu develop drug
unmet medic indic neurolog oncolog
strategi improv success rate
fda drive strong price power
oth alimta composition-of-matt patent expir
could bring gener market
weaker patent expir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qq
equival begin period
total avail debt servic
oblig commit
total oblig commit
strong cash flow deriv stabl diversifi
product portfolio remain solid financi foot
expect compani debt/ebitda level fall
close time close time
also expect debt/capit ratio fall close
cash flow accru
year strong growth prospect expect
lilli need make major acquisit drive
growth nevertheless expect tuck-in acquisit
augment growth compani next decad
adjust free
gener
gener revolv adjust
commit
gener
manufactur brand-nam drugmak also
govern managed-car organ continu
consolid purchas power exert price
challeng liabil lawsuit patent risk
cancer drug alimta sale elev
patent strong composit matter patent
increas likelihood earlier-than-expect gener
competit also strong data novo new drug
like weigh growth prospect trulic overal
rate firm uncertainti medium
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qq
view lilli stewardship rel standard
mix record capit alloc believ
lilli use billion acquir imclon
like gener good return partnership
boehring ingelheim greatli improv strateg outlook
compani verdict still regard lilli
decis spend industry-lead amount capit
percentag sale research develop
pipelin look strong phase data need
determin return invest lilli
purchas price novarti anim healthcar busi
billion appear high
entrench anim health increas lilli competit
advantag well-posit industri spin-off
busi probabl benefit novarti asset
januari dave rick took helm ceo follow
smooth transit previou ceo john lechleit
retir rick bring strong experi presid lilli
biomedicin group cover alzheim diseas
urolog immunolog musculoskelet diseas pain
well compani global market function rick
join lilli busi develop associ
dont expect major chang transit
ceo/chairman board/
repres date owner name posit common share held report holder issuer
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qq
defens natur healthcar firm offer
concern around global recess due coronaviru
disrupt weigh global market
defens natur healthcar hold rel
basi dont expect signific chang
healthcar moat rate may make downward
adjust valuat healthcar account
near-term challeng expect modest chang
rel recent stock price movement base case
call strong econom rebound follow
recess modest impact
healthcar valuat given defens natur
compani howev coronaviru pandem exert
sustain impact economi significantli higher
number patient unemploy uninsur
underinsur could reduc healthcar demand
greater extent expect govern effort reduc
near-term hit keep harder-hit industri
busi effect treatment emerg
near-term effect coronaviru expect critic
therapi crowd elect procedur new
product non-critical-car product fewer elect
procedur weigh devic maker servic
focus covid-specif case could reduc
profit health insur brand drug firm
alreadi focus specialti drug expect less impact
industri drug administ hospit could
still feel crowd coronaviru patient also
clinic develop timelin probabl face
delay due coronaviru disrupt like slow
new product launch addit coronaviru
impact credit market could weigh heavili
indebt compani hospit firm
compani recent complet major acquisit
outlook coronaviru global
economi well potenti new treatment
coronaviru pleas see
widespread diseas drug pipelin progress
outlook chang drug price polici
initi result super tuesday democrat primari
show increas support former vice presid biden
whose nomin would reduc likelihood signific
drug price polici chang line
expect dont expect major chang fair
valu estim moat rate drug biotech
industri base result continu view
industri under-valued averag
due partli excess concern around potenti major
drug polici chang note elect result
bigger impact healthcar insur servic
relief ralli health insur servic provid
drug side movement toward moder
democrat biden like mean minor drug polici
chang reduc chanc medicar
scenario champion biden key oppon sen
berni sander would like significantli reduc
drug price negoti power one-pay
system elect support shift toward biden
believ like chang drug price polici
reform center around senat bill prescript drug
price reduct act pdpra howev still believ
propos hold less chanc pass base
mix level support parti havent
includ passag bill model howev
pass estim aggreg hit brand
drug sale medicar inflat price cap part
redesign propos bill believ drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qq
biotech industri could adapt headwind
minor impact cash flow partli cost cut
increas volum base lower price mandat
bill importantli bill would limit out-of-pocket
payment patient medicar would like help
appeas demand lower drug price
new indic axial spa drive addit
growth oncolog drug verzenio continu gain share
metastat breast cancer post data earlier
patient set similar time market leader
level play field lilli larg
potenti drug polici chang key element
esg analysi drug firm pleas see recent
healthcar observ esg risk affect moat
pharma morningstar
support mani recent launch drug lilli post
post strong fourth-quart result ahead
expect rais fair valu estim
base improv outlook lilli
move period strong growth follow heavi
research develop invest past five
year influx new drug lilli help support
growth reinforc compani wide moat
oper sale growth quarter
continu next two year gener competit
fade new product continu gain traction last
heavi near-term gener pressur erectil
dysfunct drug ciali taper earli
declin gener pressur combin new product
reach critic mass drive oper margin
expans basi point
look recent launch drug lilli lead area
diabet immunolog oncolog diabet trulic
maintain leadership posit despit
increas competit novo expect label
expans higher dose favor cardiovascular
outcom data strengthen trulic posit
immunolog drug taltz continu post excel growth
pipelin lilli make stride backfil success
approv remain bullish diabet drug
tirzepatid target shown superior
phase ii data versu trulic first phase data
report earli expect approv
tirzepatid versu trulic strong compar
show confid tirzepatid
believ part lilli decis run mani phase
studi trulic support price power
tirzepatid increasingli payer use cost effect
data make coverag decis head-to-head data
versu strong drug improv price new drug
lilli price posit aspect
environment social govern includ legal
issu pleas see recent healthcar observ
esg risk affect moat valuat pharma
morningstar sustainalyt offer complementari
sustainalyt esg risk methodolog
point opportun pharma/biotech jan
sustainalyt
own
collabor broaden deepen
esg analysi incorpor environment social
govern factor valuat analysi
pharma focus
materi esg issu social realm think
firm expos esg risk morningstar
conclud valuation-affect esg risk brand
drug firm center price risk larg litig
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qq
provid comprehens evalu support
mostli wide moat rate industri
price continu view price power drug
strong central pillar support moat rate
larg drug biotechnolog compani
overal see under-valued name roch
biomarin lowest exposur esg-rel
strategi focu sever diseas lower price
pressur includ base case alreadi factor much
potenti headwind intern benchmark
price could test medicar part
biomarin global price strategi rare-diseas drug
well seriou natur condit limit futur
price litig risk despit high price tag
medicar exposur minim
import action propos
human servic juli propos rule
releas fda decemb dont view
plan major driver lower drug price think
implement chang would difficult
practic hard reconcil safeti provis
part feder track-and-trac system stop
counterfeit drug ensur enough drug-firm suppli low
price canada anoth concern drug firm could
limit distribut limit re-import also canada would
like support plan low drug price would
like face rise pressur support price
also like sanofi
valuat esg risk johnson johnson eli lilli look
least compel us base litig risk
valuat look under-valued
implement scope drug target potenti
re-import limit exclud drug biolog
inject drug drug subject fda risk evalu
mitig strategi rem drug group repres
core area focu new drug reach market
detail analysi price litig issu
top pharma name
coverag see januari
healthcar observ esg risk affect moat
pharma morningstar
trump propos drug reimport look limit
potenti lower drug price dec
trump administr move allow drug import
canada look challeng implement
limit scope dont expect major chang
fair valu estim drug biotechnolog
industri view administr move driven
polit motiv anoth elect cycl draw
near rather major structur shift influenc drug
congress support drug re-import past
safe implement propos limit
enact expect similar limit around
recent propos given complex distribut
differ drug label countri see poor
prospect wide use drug re-import
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued within
report highlight impact enact chang
drug payment increas discount
medicar part doughnut hole sale also review
depth drug polici propos council
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qq
econom advisor budget
base improv margin project dec
eli lilli host guidanc call highlight
manufactur product gain support fair valu
estim increas per share addit
lilli guid oper margin mid- high
expect reach base strong line-up
recent launch drug carri strong margin
help expand margin lilli face
patent loss next five year
strengthen return compani strong oper
posit also support wide moat rate
look promis
lilli continu make solid progress pipelin front
believ import event includ data
readout immunolog drug mirikizumab diabet
drug tirzepatid mirikizumab enter psoriasi
market later competit agent posit
competit uc space also first phase studi
tirzepatid show posit data new
mechan action drug hold potenti
stronger effect drug like lilli trulic
lilli also report phase data alzheim drug
solanezumab high-dos set dont factor
sale riski studi given drug failur
studi lastli compani continu push
forward regulatori submiss pain drug
tanezumab although estim chanc
approv given poor side effect profil howev
either solanezumab tanezumab reach market lilli
strong growth prospect could improv
price gener headwind acceler
post steadi remain posit oct
report third-quart result larg line
expect slow sale growth diabet drug
trulic immunolog drug taltz like weigh
stock price dont expect make major chang
fair valu estim view stock pullback
overdon continu view lilli wide moat
one well-round portfolio current
market drug pipelin drug across stage
launch drug
quarter total sale increas oper
despit major gener pressur erectil dysfunct drug
ciali sever new drug post solid gain sheer
number recent
lead
acceler growth margin expans close
basi point gener pressur annual
remain bullish diabet drug jardianc driven like
indic expans trulic support favor
aid new indic favor head-to-head data
strong overal surviv data migrain drug emgal
enter larg potenti market
gain synergi lilli recent approv acut
migrain drug reyvow despit overal strong
posit current portfolio acknowledg
like slow growth trulic face competit
easier take oral drug rybelsu novo also
taltz face increas competit new psoriasi
complet review lilli pipelin current
report moat remain secur innov counter
beyond current portfolio lilli continu back fill
remain bullish late-stag drug trizepatid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qq
diabet mirikizumab immunolog addit
sever early-stag drug potenti game changer
diseas like alzheim dementia cancer also
carri higher uncertainti success
complet review lilli pipelin current
report moat remain secur innov counter
price gener headwind acceler
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qq
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qq
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
